Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

3.593 +0.163 (+4.76%)
Streaming Delayed Price Updated: 12:02 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immix Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
From Immix Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Other Serious Diseases Strategy
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Attends FDA CEO Forum in Washington DC
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session.
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
On Tuesday, there are stocks with unusual volume. Let's take a look.
Volume analysis on 2025-05-27: stocks with an unusual volume in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
Discover the top movers in Friday's pre-market session.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Intuit Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Thursday's after hours session: top gainers and losers
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.